Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998;78(Suppl 3):21–25. doi: 10.1038/bjc.1998.750

The role of gemcitabine in the treatment of other tumours.

J Carmichael 1
PMCID: PMC2062798  PMID: 9717987

Abstract

Gemcitabine (GEMZAR) is a novel nucleoside analogue with activity in a range of preclinical models both in vitro and in vivo. It is highly schedule dependent, with weekly x3 every 4 weeks being the recommended schedule for phase II/III studies. Early phase II trials identified activity against non-small-cell lung cancer and pancreatic cancers, tumour types for which gemcitabine has a licence for treatment in many countries. However, the preclinical models indicated that gemcitabine may be active against many other human solid tumours. In phase II studies, activity has been identified against breast cancer, both as a single agent and in combination. In bladder cancer, impressive single-agent activity of gemcitabine has also been seen, as well as in combination with cisplatin, initially in MVAC and platinum failures but more recently as first-line therapy both as a single agent and combined with cisplatin. Anti-tumour activity has also been seen in patients with ovarian cancer, head and neck cancer, small-cell lung cancer and cervical cancer, with minimal activity in renal carcinoma, prostate and colon cancer. In view of the excellent side-effect profile and the potential for gemcitabine to inhibit DNA repair after exposure to DNA-damaging agents, further developments of gemcitabine will include its use in combination chemotherapy and combined modality schedules.

Full text

PDF
23

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abratt R. P., Bezwoda W. R., Falkson G., Goedhals L., Hacking D., Rugg T. A. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994 Aug;12(8):1535–1540. doi: 10.1200/JCO.1994.12.8.1535. [DOI] [PubMed] [Google Scholar]
  2. Abratt R. P., Bezwoda W. R., Goedhals L., Hacking D. J. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 1997 Feb;15(2):744–749. doi: 10.1200/JCO.1997.15.2.744. [DOI] [PubMed] [Google Scholar]
  3. Anderson H., Lund B., Bach F., Thatcher N., Walling J., Hansen H. H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994 Sep;12(9):1821–1826. doi: 10.1200/JCO.1994.12.9.1821. [DOI] [PubMed] [Google Scholar]
  4. Braakhuis B. J., van Dongen G. A., Vermorken J. B., Snow G. B. Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. Cancer Res. 1991 Jan 1;51(1):211–214. [PubMed] [Google Scholar]
  5. Burris H. A., 3rd, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413. doi: 10.1200/JCO.1997.15.6.2403. [DOI] [PubMed] [Google Scholar]
  6. Carmichael J., Allerheiligen S., Walling J. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol. 1996 Oct;23(5 Suppl 10):55–59. [PubMed] [Google Scholar]
  7. Carmichael J., Possinger K., Phillip P., Beykirch M., Kerr H., Walling J., Harris A. L. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995 Nov;13(11):2731–2736. doi: 10.1200/JCO.1995.13.11.2731. [DOI] [PubMed] [Google Scholar]
  8. Carmichael J., Walling J. Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol. 1996 Oct;23(5 Suppl 10):77–81. [PubMed] [Google Scholar]
  9. Casper E. S., Green M. R., Kelsen D. P., Heelan R. T., Brown T. D., Flombaum C. D., Trochanowski B., Tarassoff P. G. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12(1):29–34. doi: 10.1007/BF00873232. [DOI] [PubMed] [Google Scholar]
  10. Cormier Y., Eisenhauer E., Muldal A., Gregg R., Ayoub J., Goss G., Stewart D., Tarasoff P., Wong D. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1994 Mar;5(3):283–285. doi: 10.1093/oxfordjournals.annonc.a058808. [DOI] [PubMed] [Google Scholar]
  11. Crinò L., Scagliotti G., Marangolo M., Figoli F., Clerici M., De Marinis F., Salvati F., Cruciani G., Dogliotti L., Pucci F. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1997 Jan;15(1):297–303. doi: 10.1200/JCO.1997.15.1.297. [DOI] [PubMed] [Google Scholar]
  12. De Mulder P. H., Weissbach L., Jakse G., Osieka R., Blatter J. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol. 1996;37(5):491–495. doi: 10.1007/s002800050417. [DOI] [PubMed] [Google Scholar]
  13. Gatzemeier U., Shepherd F. A., Le Chevalier T., Weynants P., Cottier B., Groen H. J., Rosso R., Mattson K., Cortes-Funes H., Tonato M. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer. 1996 Feb;32A(2):243–248. doi: 10.1016/0959-8049(95)00444-0. [DOI] [PubMed] [Google Scholar]
  14. Heinemann V., Xu Y. Z., Chubb S., Sen A., Hertel L. W., Grindey G. B., Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol. 1990 Oct;38(4):567–572. [PubMed] [Google Scholar]
  15. Huang P., Chubb S., Hertel L. W., Grindey G. B., Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991 Nov 15;51(22):6110–6117. [PubMed] [Google Scholar]
  16. Kaye S. B. Gemcitabine: current status of phase I and II trials. J Clin Oncol. 1994 Aug;12(8):1527–1531. doi: 10.1200/JCO.1994.12.8.1527. [DOI] [PubMed] [Google Scholar]
  17. Lund B., Hansen O. P., Theilade K., Hansen M., Neijt J. P. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994 Oct 19;86(20):1530–1533. doi: 10.1093/jnci/86.20.1530. [DOI] [PubMed] [Google Scholar]
  18. Mertens W. C., Eisenhauer E. A., Moore M., Venner P., Stewart D., Muldal A., Wong D. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1993 Apr;4(4):331–332. doi: 10.1093/oxfordjournals.annonc.a058494. [DOI] [PubMed] [Google Scholar]
  19. Pollera C. F., Ceribelli A., Crecco M., Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol. 1994 Feb;5(2):182–184. doi: 10.1093/oxfordjournals.annonc.a058775. [DOI] [PubMed] [Google Scholar]
  20. Rabbolini S., Verardo E., Da Col M., Gioacchini A. M., Traldi P. Negative ion electrospray ionization tandem mass spectrometry in the structural characterization of penicillins. Rapid Commun Mass Spectrom. 1998;12(22):1820–1826. doi: 10.1002/(SICI)1097-0231(19981130)12:22<1820::AID-RCM387>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  21. Shapiro J. D., Millward M. J., Rischin D., Michael M., Walcher V., Francis P. A., Toner G. C. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996 Oct;63(1):89–93. doi: 10.1006/gyno.1996.0284. [DOI] [PubMed] [Google Scholar]
  22. Von Hoff D. D. Gemcitabine: a case study for clinical benefit. Semin Oncol. 1996 Oct;23(5 Suppl 10):1–2. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES